Less than 10% of primary CRC and 5.1%–8.2% of metastatic CRC (mCRC) patients have mutations in the v-raf murine sarcoma viral oncogene homolog B (BRAF) gene (2–5). This evidence concerns the gene BRAF and colorectal carcinoma.